HUE058212T2 - 2-((1-(2(4-fluorfenil)-2-oxoetil)piperidin-4-il)metil)izoindolin-1-ont tartalmazó készítmények skizofrénia kezelésére - Google Patents
2-((1-(2(4-fluorfenil)-2-oxoetil)piperidin-4-il)metil)izoindolin-1-ont tartalmazó készítmények skizofrénia kezeléséreInfo
- Publication number
- HUE058212T2 HUE058212T2 HUE15808314A HUE15808314A HUE058212T2 HU E058212 T2 HUE058212 T2 HU E058212T2 HU E15808314 A HUE15808314 A HU E15808314A HU E15808314 A HUE15808314 A HU E15808314A HU E058212 T2 HUE058212 T2 HU E058212T2
- Authority
- HU
- Hungary
- Prior art keywords
- isoindolin
- oxoethyl
- piperidin
- fluorophenyl
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- RNRYULFRLCBRQS-UHFFFAOYSA-N roluperidone Chemical compound C1=CC(F)=CC=C1C(=O)CN1CCC(CN2C(C3=CC=CC=C3C2)=O)CC1 RNRYULFRLCBRQS-UHFFFAOYSA-N 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462086691P | 2014-12-02 | 2014-12-02 | |
US201562248071P | 2015-10-29 | 2015-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE058212T2 true HUE058212T2 (hu) | 2022-07-28 |
Family
ID=54848909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE15808314A HUE058212T2 (hu) | 2014-12-02 | 2015-11-30 | 2-((1-(2(4-fluorfenil)-2-oxoetil)piperidin-4-il)metil)izoindolin-1-ont tartalmazó készítmények skizofrénia kezelésére |
Country Status (26)
Country | Link |
---|---|
US (6) | US9458130B2 (hu) |
EP (2) | EP3227273B1 (hu) |
JP (3) | JP2018501217A (hu) |
KR (1) | KR102620681B1 (hu) |
CN (2) | CN107567444A (hu) |
AU (4) | AU2015355226B2 (hu) |
BR (1) | BR112017011555B1 (hu) |
CA (1) | CA2968977A1 (hu) |
CL (2) | CL2017001376A1 (hu) |
CO (1) | CO2017005498A2 (hu) |
DK (1) | DK3227273T3 (hu) |
EA (1) | EA201791226A1 (hu) |
ES (1) | ES2910528T3 (hu) |
HU (1) | HUE058212T2 (hu) |
IL (3) | IL301320A (hu) |
MX (1) | MX2017007065A (hu) |
MY (1) | MY185516A (hu) |
PE (1) | PE20171646A1 (hu) |
PH (1) | PH12017501007A1 (hu) |
PL (1) | PL3227273T3 (hu) |
PT (1) | PT3227273T (hu) |
SG (1) | SG11201704332YA (hu) |
TW (1) | TWI694069B (hu) |
UA (1) | UA122780C2 (hu) |
WO (1) | WO2016089766A1 (hu) |
ZA (1) | ZA201703481B (hu) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016089766A1 (en) * | 2014-12-02 | 2016-06-09 | Minerva Neurosciences, Inc. | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
KR20190013846A (ko) * | 2016-05-25 | 2019-02-11 | 미쓰비시 타나베 파마 코퍼레이션 | 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법 |
AU2018290287B2 (en) * | 2017-06-21 | 2024-06-13 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
CN107721988A (zh) * | 2017-10-31 | 2018-02-23 | 无锡福祈制药有限公司 | 具有抗炎活性的异吲哚‑1‑酮类化合物 |
WO2020041504A1 (en) * | 2018-08-21 | 2020-02-27 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
EP3990113A1 (en) | 2019-06-28 | 2022-05-04 | Teva Czech Industries s.r.o. | Solid state forms of roluperidone and salts thereof |
WO2021236879A1 (en) | 2020-05-20 | 2021-11-25 | The Board Of Trustees Of The University Of Illinois | Method for treating lysosomal storage diseases with histatin peptides |
WO2023154927A1 (en) | 2022-02-14 | 2023-08-17 | Minerva Neurosciences, Inc. | Use of roluperidone in preventing relapse in schizophrenia patients |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
ATE102482T1 (de) | 1988-01-21 | 1994-03-15 | Merrell Dow Pharma | Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit. |
WO1991006297A1 (en) | 1989-10-27 | 1991-05-16 | The Du Pont Merck Pharmaceutical Company | (n-phthalimidoalkyl) piperidines |
FR2797643B1 (fr) | 1999-08-17 | 2003-06-06 | Rhodia Chimie Sa | Utilisation composes terpeniques polyoxypropylenes/ polyoxyethylenes comme agent de degraissage de surfaces dures |
ES2291293T3 (es) * | 2000-02-29 | 2008-03-01 | Mitsubishi Pharma Corporation | Nuevos derivados amida ciclicos. |
PT1372611E (pt) * | 2001-03-26 | 2006-08-31 | Novartis Ag | Composicao farmaceutica compreendendo uma estaurosporina francamente soluvel em agua, um tensioactivo et um polimero soluvel em agua |
CA2609969C (en) | 2005-06-06 | 2015-10-27 | Merck Sharp & Dohme Limited | Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia |
CA2569776A1 (en) * | 2006-02-17 | 2007-08-17 | Kos Life Sciences, Inc. | Low flush niacin formulation |
GB2462611A (en) * | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
US8937900B2 (en) * | 2010-07-20 | 2015-01-20 | Qualcomm Incorporated | Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies |
RS64819B1 (sr) * | 2010-07-20 | 2023-12-29 | Minerva Neurosciences Inc | Metode upotrebe derivata cikličnih amida za lečenje šizofrenije i njenih simptoma |
CA2805904C (en) * | 2010-07-20 | 2022-06-21 | Cyrenaic Pharmaceuticals, Inc. | Use of cyclic amide derivatives to treat sigma receptor-mediated disorders |
EP2468264A1 (en) | 2010-12-27 | 2012-06-27 | Laboratorios Liconsa, S.A. | Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it |
US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
KR20140045925A (ko) * | 2011-03-17 | 2014-04-17 | 루핀 리미티드 | 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물 |
US10179776B2 (en) | 2014-06-09 | 2019-01-15 | Intra-Cellular Therapies, Inc. | Compounds and methods of use to treat schizophrenia |
WO2016089766A1 (en) | 2014-12-02 | 2016-06-09 | Minerva Neurosciences, Inc. | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
KR20190013846A (ko) | 2016-05-25 | 2019-02-11 | 미쓰비시 타나베 파마 코퍼레이션 | 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법 |
AU2018290287B2 (en) | 2017-06-21 | 2024-06-13 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
WO2020041504A1 (en) | 2018-08-21 | 2020-02-27 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
-
2015
- 2015-11-30 WO PCT/US2015/062985 patent/WO2016089766A1/en active Application Filing
- 2015-11-30 DK DK15808314.7T patent/DK3227273T3/da active
- 2015-11-30 BR BR112017011555-7A patent/BR112017011555B1/pt active IP Right Grant
- 2015-11-30 PL PL15808314T patent/PL3227273T3/pl unknown
- 2015-11-30 EP EP15808314.7A patent/EP3227273B1/en active Active
- 2015-11-30 IL IL301320A patent/IL301320A/en unknown
- 2015-11-30 IL IL280052A patent/IL280052B2/en unknown
- 2015-11-30 TW TW104139904A patent/TWI694069B/zh active
- 2015-11-30 JP JP2017529388A patent/JP2018501217A/ja active Pending
- 2015-11-30 AU AU2015355226A patent/AU2015355226B2/en active Active
- 2015-11-30 MY MYPI2017701998A patent/MY185516A/en unknown
- 2015-11-30 SG SG11201704332YA patent/SG11201704332YA/en unknown
- 2015-11-30 PE PE2017000948A patent/PE20171646A1/es unknown
- 2015-11-30 US US14/954,264 patent/US9458130B2/en active Active
- 2015-11-30 EP EP22155504.8A patent/EP4063357A1/en active Pending
- 2015-11-30 CN CN201580065471.3A patent/CN107567444A/zh active Pending
- 2015-11-30 UA UAA201706785A patent/UA122780C2/uk unknown
- 2015-11-30 EA EA201791226A patent/EA201791226A1/ru unknown
- 2015-11-30 PT PT158083147T patent/PT3227273T/pt unknown
- 2015-11-30 CN CN202010012498.9A patent/CN111110677A/zh active Pending
- 2015-11-30 KR KR1020177018088A patent/KR102620681B1/ko active IP Right Grant
- 2015-11-30 HU HUE15808314A patent/HUE058212T2/hu unknown
- 2015-11-30 ES ES15808314T patent/ES2910528T3/es active Active
- 2015-11-30 MX MX2017007065A patent/MX2017007065A/es unknown
- 2015-11-30 CA CA2968977A patent/CA2968977A1/en active Pending
-
2016
- 2016-09-28 US US15/278,421 patent/US9730920B2/en active Active
-
2017
- 2017-05-17 IL IL252347A patent/IL252347B/en active IP Right Grant
- 2017-05-19 ZA ZA2017/03481A patent/ZA201703481B/en unknown
- 2017-05-30 CL CL2017001376A patent/CL2017001376A1/es unknown
- 2017-05-31 PH PH12017501007A patent/PH12017501007A1/en unknown
- 2017-05-31 CO CONC2017/0005498A patent/CO2017005498A2/es unknown
- 2017-07-17 US US15/651,065 patent/US10258614B2/en active Active
-
2019
- 2019-03-01 US US16/290,234 patent/US10799493B2/en active Active
-
2020
- 2020-06-26 AU AU2020204286A patent/AU2020204286B2/en active Active
- 2020-07-06 JP JP2020116157A patent/JP7069253B2/ja active Active
- 2020-09-11 US US17/017,816 patent/US20210228561A1/en not_active Abandoned
-
2021
- 2021-01-07 CL CL2021000044A patent/CL2021000044A1/es unknown
- 2021-09-10 AU AU2021229240A patent/AU2021229240B2/en active Active
-
2022
- 2022-05-02 JP JP2022076280A patent/JP2022105159A/ja active Pending
-
2023
- 2023-02-17 US US18/111,072 patent/US20230201184A1/en active Pending
- 2023-11-01 AU AU2023258386A patent/AU2023258386A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280052A (en) | Preparations containing 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidine-4-yl)methyl)isoindoline-1-one for the treatment of schizophrenia | |
IL291533A (en) | Compounds and preparations including them for the treatment of diseases of the central nervous system | |
IL304398A (en) | Preparations and methods for genome modification | |
HK1256817A1 (zh) | 用於基因組編輯的組合物和方法 | |
HK1231411A1 (zh) | 作為 抑制劑的取代的吲唑化合物 | |
IL287517A (en) | Benzimidazole compounds as c-kit inhibitors | |
HK1231480A1 (zh) | 作為 抑制劑的吲唑化合物 | |
IL246875A0 (en) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as bace1 inhibitors for the treatment of Alzheimer's disease | |
HK1251566A1 (zh) | 作為hdac1/2抑制劑的呱啶衍生物 | |
SG11201610217YA (en) | 2-(3-pyridinyl)-1h-benzimidazole derivative compound and medicine containing same | |
SG11201701771YA (en) | Composition for removing photoresist residue and/or polymer residue | |
IL248779A0 (en) | Pharmaceutical preparations for the treatment of infectious diseases | |
IL265255A (en) | Dementia treatment preparations | |
HK1250627A1 (zh) | 用於治療hcv的固體藥物組合物 | |
IL274821A (en) | Substances that inhibit MPGES-1 and their uses | |
IL261958A (en) | Formulations for treating constipation | |
HK1248551A1 (zh) | 用於治療精神分裂症的伊潘立酮 | |
EP3529243C0 (en) | (Z)-3-(2-(5-BROMO-1H-INDOL-3-YL)-2-CYANOVINYL)-4-METHOXYBENZONITRILE FOR THE TREATMENT OF ENDOMETRIOSIS | |
ITCR20140001U1 (it) | Pinza operatoria per l'inserimento semplificato di uno shunt coronarico | |
FR3022905B1 (fr) | Composition pour joints |